Literature DB >> 9416511

Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis.

K M Drescher1, L R Pease, M Rodriguez.   

Abstract

The spectrum of disease is influenced by factors related to both the pathogen and the host, as well as the end points used in defining disease. In this article, the issue of disease resistance versus susceptibility will be examined in the framework that genetic manipulation of either the pathogen or the host immune response alters the balance from disease protection towards pathogenesis. The response of the host may trigger both a protective and a pathogenic immune response. The failure to mount a protective immune response predisposes the pathogen to persistence, which then becomes the target for immunopathology. This review will examine the factors involved both in virus-mediated pathogenesis and in disease protection in the Theiler's model of human multiple sclerosis. By manipulating the character of the virus pathogen and the specificity of the immune response, the entire spectrum of human demyelinating disease is reproduced.

Entities:  

Mesh:

Year:  1997        PMID: 9416511     DOI: 10.1111/j.1600-065x.1997.tb01015.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  20 in total

1.  Prevalent class I-restricted T-cell response to the Theiler's virus epitope Db:VP2121-130 in the absence of endogenous CD4 help, tumor necrosis factor alpha, gamma interferon, perforin, or costimulation through CD28.

Authors:  A J Johnson; M K Njenga; M J Hansen; S T Kuhns; L Chen; M Rodriguez; L R Pease
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Two loci, Tmevp2 and Tmevp3, located on the telomeric region of chromosome 10, control the persistence of Theiler's virus in the central nervous system of mice.

Authors:  F Bihl; M Brahic; J F Bureau
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

3.  Influence of the Theiler's virus L* protein on macrophage infection, viral persistence, and neurovirulence.

Authors:  O van Eyll; T Michiels
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Control of central nervous system viral persistence by neutralizing antibody.

Authors:  Chandran Ramakrishna; Cornelia C Bergmann; Roscoe Atkinson; Stephen A Stohlman
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

5.  Induction of autoreactive CD8+ cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity.

Authors:  Ikuo Tsunoda; Li-Qing Kuang; Robert S Fujinami
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Non-AUG-initiated internal translation of the L* protein of Theiler's virus and importance of this protein for viral persistence.

Authors:  Olivier van Eyll; Thomas Michiels
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  The leader protein of Theiler's virus interferes with nucleocytoplasmic trafficking of cellular proteins.

Authors:  Sophie Delhaye; Vincent van Pesch; Thomas Michiels
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Central nervous system pathology caused by autoreactive CD8+ T-cell clones following virus infection.

Authors:  Ikuo Tsunoda; Li-Qing Kuang; Mikako Kobayashi-Warren; Robert S Fujinami
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

9.  Neuroprotective action of hypothalamic peptide PRP-1 at various time survivals following spinal cord hemisection.

Authors:  Armen A Galoyan; John S Sarkissian; Vergine A Chavushyan; Ruben M Sulkhanyan; Zaruhi E Avakyan; Zubeida A Avetisyan; Yuri Kh Grigorian; Davit O Abrahamyan
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

10.  H-2D(b-/-) mice are susceptible to persistent infection by Theiler's virus.

Authors:  A Azoulay-Cayla; S Dethlefs; B Pérarnau; E L Larsson-Sciard; F A Lemonnier; M Brahic; J F Bureau
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.